PHAR vs ACAD vs LGND vs PRAX vs RARE

For growth investors, Ligand Pharmaceuticals Incorporated (LGND) is the stronger pick with 27.

3% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 8x trailing P/E (55. 6x forward), making it the more compelling value choice. Analysts rate Pharming Group N. V. (PHAR) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACADIA Pharmaceuticals Inc.

(ACAD) is the cheapest at 9. 8x versus Pharming Group N. V. at 324. 5x. On forward P/E, Ligand Pharmaceuticals Incorporated is actually cheaper at 24. 6x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Ligand Pharmaceuticals Incorporated (LGND) delivered a total return of +74.

8%, compared to -76. 1% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: LGND returned +82. 2% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ligand Pharmaceuticals Incorporated (LGND) is the lower-risk stock at 1.

03β versus Praxis Precision Medicines, Inc. 's 1. 40β — meaning PRAX is approximately 37% more volatile than LGND relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 42% for Pharming Group N. V. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ligand Pharmaceuticals Incorporated (LGND) is pulling ahead at 27.

3% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Pharming Group N. V. grew EPS 123. 5% year-over-year, compared to -107. 5% for Ligand Pharmaceuticals Incorporated. Over a 3-year CAGR, ACAD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -79. 5% for RARE. At the gross margin level — before operating expenses — LGND leads at 93. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Ligand Pharmaceuticals Incorporated (LGND) trades at 24.

6x forward P/E versus 66. 5x for Pharming Group N. V. — 41. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PHAR: 192. 8% to $38. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Ligand Pharmaceuticals Incorporated (LGND) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

03)). Both have compounded well over 10 years (LGND: +82. 2%, PRAX: -20. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PHAR is a small-cap high-growth stock; ACAD is a small-cap deep-value stock; LGND is a small-cap high-growth stock; PRAX is a small-cap quality compounder stock; RARE is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.